Madrigal's Billion-Dollar Bet on Silencing Genes
Madrigal Pharmaceuticals just paid up to $1 billion for a gene-silencing drug to pair with its blockbuster MASH therapy Rezdiffra. It's the third major deal in a year as the company races to build an unbeatable liver disease franchise before Novo Nordisk and others crash the party.
The MASH King Wants a Bigger Castle
Madrigal Pharmaceuticals already owns the only approved drug for MASH, the severe liver disease formerly known as NASH. That drug, Rezdiffra, pulled in $958 million in its first full year of sales. So why is Madrigal writing checks to other companies?
Because one drug isn't enough to own a disease that affects tens of millions of people. And on May 5, Madrigal signed an exclusive worldwide license with Arrowhead Pharmaceuticals for a gene-silencing therapy called ARO-PNPLA3. The deal: $25 million upfront, with up to $975 million more in milestone payments. Total potential value: roughly $1 billion.
This isn't a desperation move. It's an empire-building one.
What Exactly Did They Buy?
ARO-PNPLA3 is an RNAi therapeutic. RNAi (RNA interference) works like a mute button for specific genes. Instead of blocking a protein after it's already been made, RNAi intercepts the genetic instructions beforehand, preventing the harmful protein from ever being produced.
In this case, the target is a gene called PNPLA3. A specific mutation in that gene (called I148M) makes liver disease significantly worse for the people who carry it. About 30% of MASH patients carry this mutation.
In Phase 1 testing, ARO-PNPLA3 reduced liver fat by up to 46% at 12 weeks. Those benefits appeared as early as six weeks after a single dose and lasted out to 24 weeks. For a disease where liver fat accumulation drives progression to cirrhosis and liver failure, those numbers matter.
The Combo Playbook
Think of Rezdiffra as a broad-spectrum antibiotic for MASH. It works across the general patient population by activating a thyroid hormone receptor in the liver. ARO-PNPLA3, by contrast, is a precision strike: it only helps the subset of patients with that specific genetic mutation.
Madrigal's plan is to combine the two. Give patients the broad-acting pill (Rezdiffra) plus the gene-silencing injection (ARO-PNPLA3) for a one-two punch. The company is already in discussions with the FDA about designing a Phase 2 combination trial.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
